These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 14707152)

  • 21. Comparative effects of olmesartan and azelnidipine on atrial structural remodeling in spontaneously hypertensive rats.
    Okamura K; Ito M; Tanaka K; Chinushi M; Adachi T; Mitsuma W; Hirono S; Nakazawa M; Kodama M; Aizawa Y
    Pharmacology; 2009; 83(6):360-6. PubMed ID: 19440002
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study.
    Kojima M; Okubo S; Mizubayashi R; Isaka N; Machida H; Okamoto S; Hirota H; Takeuchi M; Kato T; Nakatani K; Mizuno O; Miyagawa K; Makino K; Okura T; Dohi Y; Ito M; Kimura G
    Nephrol Dial Transplant; 2013 Jul; 28(7):1802-10. PubMed ID: 23535223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of combination therapy of olmesartan plus azelnidipine or hydrochlorothiazide on renal and vascular damage in SHR/NDmcr-cp rats.
    Nagasu H; Satoh M; Yorimitsu D; Tomita N; Sasaki T; Kashihara N
    Kidney Blood Press Res; 2011; 34(2):87-96. PubMed ID: 21273789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of combination therapy with olmesartan and azelnidipine on serum osteoprotegerin in patients with hypertension.
    Uzui H; Morishita T; Nakano A; Amaya N; Fukuoka Y; Ishida K; Arakawa K; Lee JD; Tada H
    J Cardiovasc Pharmacol Ther; 2014 May; 19(3):304-9. PubMed ID: 24288395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
    Ogawa H; Kim-Mitsuyama S; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
    Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress.
    Tsuda M; Iwai M; Li JM; Li HS; Min LJ; Ide A; Okumura M; Suzuki J; Mogi M; Suzuki H; Horiuchi M
    Hypertension; 2005 Apr; 45(4):545-51. PubMed ID: 15723967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapy with olmesartan and azelnidipine improves EDHF-mediated responses in diabetic apolipoprotein E-deficient mice.
    Hosoya M; Ohashi J; Sawada A; Takaki A; Shimokawa H
    Circ J; 2010 Apr; 74(4):798-806. PubMed ID: 20154404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination therapy of olmesartan and azelnidipine inhibits sympathetic activity associated with reducing oxidative stress in the brain of hypertensive rats.
    Shinohara K; Hirooka Y; Ogawa K; Kishi T; Yasukawa K; Utsumi H; Sunagawa K
    Clin Exp Hypertens; 2012; 34(6):456-62. PubMed ID: 22471901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced pulsatile pressure accelerates vascular smooth muscle migration: implications for atherogenesis of hypertension.
    Tada T; Nawata J; Wang H; Onoue N; Zhulanqiqige D; Ito K; Sugimura K; Fukumoto Y; Shimokawa H
    Cardiovasc Res; 2008 Dec; 80(3):346-53. PubMed ID: 18687705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Olmesartan medoxomil and azelnidipine therapy in patients with hypertension and chronic kidney disease in Japan.
    Saito I; Kushiro T; Zenimura N; Matsushita Y; Sagawa K; Hiramatsu K; Yamaguchi F
    J Nephrol; 2012; 25(5):699-708. PubMed ID: 22020401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A third-generation, long-acting, dihydropyridine calcium antagonist, azelnidipine, attenuates stent-associated neointimal formation in non-human primates.
    Nakano K; Egashira K; Tada H; Kohjimoto Y; Hirouchi Y; Kitajima S; Endo Y; Li XH; Sunagawa K
    J Hypertens; 2006 Sep; 24(9):1881-9. PubMed ID: 16915039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study.
    Takami T; Saito Y
    Vasc Health Risk Manag; 2011; 7():383-90. PubMed ID: 21796252
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Azelnidipine has anti-atherosclerotic effects independent of its blood pressure-lowering actions in monkeys and mice.
    Nakano K; Egashira K; Ohtani K; Gang Z; Iwata E; Miyagawa M; Sunagawa K
    Atherosclerosis; 2008 Jan; 196(1):172-179. PubMed ID: 17481639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
    Shimada K; Ogihara T; Saruta T; Kuramoto K;
    Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibitory effects of a dihydropyridine calcium channel blocker on renal injury in aldosterone-infused rats.
    Fan YY; Kohno M; Nakano D; Hitomi H; Nagai Y; Fujisawa Y; Lu XM; Fu H; Du J; Ohmori K; Hosomi N; Kimura S; Kiyomoto H; Nishiyama A
    J Hypertens; 2009 Sep; 27(9):1855-62. PubMed ID: 19633569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sex differences in response to angiotensin II receptor blocker-based therapy in elderly, high-risk, hypertensive Japanese patients: a subanalysis of the OSCAR study.
    Matsui K; Kim-Mitsuyama S; Ogawa H; Jinnouchi T; Jinnouchi H; Arakawa K;
    Hypertens Res; 2014 Jun; 37(6):526-32. PubMed ID: 24599010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Azelnidipine, a new calcium channel blocker, inhibits endothelial inflammatory response by reducing intracellular levels of reactive oxygen species.
    Naito Y; Shimozawa M; Manabe H; Nakabe N; Katada K; Kokura S; Yoshida N; Ichikawa H; Kon T; Yoshikawa T
    Eur J Pharmacol; 2006 Sep; 546(1-3):11-8. PubMed ID: 16919261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Olmesartan with azelnidipine versus with trichlormethiazide on home blood pressure variability in patients with type II diabetes mellitus.
    Ushigome E; Matsumoto S; Oyabu C; Ushigome H; Yokota I; Hasegawa G; Nakamura N; Tanaka M; Yamazaki M; Fukui M
    J Am Soc Hypertens; 2017 Mar; 11(3):140-147. PubMed ID: 28089902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Azelnidipine is a calcium blocker that attenuates liver fibrosis and may increase antioxidant defence.
    Ohyama T; Sato K; Kishimoto K; Yamazaki Y; Horiguchi N; Ichikawa T; Kakizaki S; Takagi H; Izumi T; Mori M
    Br J Pharmacol; 2012 Feb; 165(4b):1173-87. PubMed ID: 21790536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.